Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers April 23, 2014
Pharmacy Choice - News - Generic Drugs - April 23, 2014

Pharmacy News

 Generic Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 58     Next >>     Go To Page:

4/22/14 - Actavis Announces Departure of G. Frederick Wilkinson, President, Actavis Global R%7ED [Global Data Point]
"Over the past five years, Fred has played an essential role in our evolution from a primarily generics company to a leading specialty pharmaceutical company," said Paul M. Bisaro, Chairman and CEO of Actavis. He was also instrumental in establishing our biosimilar strategy, which today includes five products in development, including four under th
4/22/14 - Actavis to Purchase 4 Products from Akorn [Professional Services Close - Up]
Actavis plc, a global specialty pharmaceutical company, announced that it has entered into agreements with Akorn, Inc. and Hi-Tech Pharmacal Co. Inc. to purchase four currently marketed products and one product under development for cash consideration. The closing of the purchase agreements are contingent upon the consummation of Akorn's acquisitio
4/22/14 - Akorn Completes Acquisition of Hi-Tech Pharmacal [Manufacturing Close - Up]
Akorn, Inc., a niche pharmaceutical company, announced that it has completed its previously announced acquisition of Hi-Tech Pharmacal Co., Inc. for $640 million in cash. According to a release, the combination of Akorn and Hi-Tech will transform the Company into a larger, more diversified generic player. This combination also brings critical mass
4/22/14 - Analysts: Chances of generic Copaxone low [Globes, Tel Aviv, Israel :: ]
April 22 The Supreme Court's decision against Teva Pharmaceutical Industries Ltd.' s request to block a potential launch of generic Copaxone pending the outcome of the hearing on the patent later this year is not surprising, says Citi Research in response to the Supreme Court's decision on Friday, adding that it's investment thesis remains unchan
4/22/14 - Eli Lilly and Company, et al.; Withdrawal of Approval of 3 New Drug Applications and 41 Abbreviated New Drug Applications
FOR FURTHER INFORMATION CONTACT: Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6366, Silver Spring, MD 20993-0002, 301-796-3601.. SUPPLEMENTARY INFORMATION: The holders of the applications listed in table 1 in this document have informed FDA that these drug products
4/22/14 - Flood Law Group Updates Actos Lawsuit Information Page after Jury Hands Down $9 Billion Settlement
Flood Law Group today announced that they have added updated content to their informational webpage dedicated to lawsuits related to the prescription drug Actos. Roughly 2,700 lawsuits against Takeda Pharmaceutical Co. and Eli Lilly& Co. have been consolidated under MDL No. 2299 at the U.S. District Court for the Western District of Louisiana.
4/22/14 - Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics
Novartis International AG/ Novartis announces portfolio transformation, focusing company on leading businesses with innovation power and global scale: Pharmaceuticals, Eye Care and Generics. *Acquires GSK oncology products, strengthening Novartis' leading Oncology business with novel therapies and becomes GSK's preferred commercialization partner..
4/22/14 - Research and Markets Adds Report: Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines [Travel & Leisure Close - Up]
Research and Markets has announced the addition of the "Public Knowledge, Perceptions, and Intentions for Biologic and Biosimilar Medicines" report to its offerings. In a release, Research and Markets noted that report highlights include:. This research was designed to provide pharmaceutical sales, marketing, and brand management with data to bette
4/22/14 - The Global Biosimilars Pipeline Has Expanded by Over 40 Percent in the Last 12 Months
Decision Resources Group finds that the number of publically disclosed biosimilar development projects has increased by more than 40 percent in the last 12 months. The majority of these development projects are yet to enter clinical development, but the 20 percent annual increase in the number of biosimilars in clinical trials indicates substantial
4/21/14 - Ampio Pharmaceuticals' Vyrix Enters into an Agreement with Paladin Labs for Exclusive Rights to Zertane? in Canada and Other Territories to Broaden...
Ampio Pharmaceuticals' Vyrix Enters into an Agreement with Paladin Labs for Exclusive Rights to Zertane? in Canada and Other Territories to Broaden its International Footprint. By a News Reporter-Staff News Editor at Clinical Trials Week Ampio Pharmaceuticals Inc. announced that its wholly-owned subsidiary Vyrix Pharmaceuticals, a specialty...
4/21/14 - BocaGreenMD Launches Prena1 Pearl?, the Only Generic Version of vitaMedMD's vitaPearl?
By a News Reporter-Staff News Editor at Pharma Business Week TherapeuticsMD, Inc., parent company of BocaGreenMD, Inc., announced the launch of Prena1 Pearl, BocaGreen's generic formulation of vitaMedMD, Inc.' s newest prescription prenatal multivitamin, vitaPearl. vitaPearl is a pearl-shaped softgel that is currently the smallest complete prescr
4/21/14 - Federal Judge Enforces Settlement Agreement Between Mylan and Endo Regarding Generic FROVA
By a News Reporter-Staff News Editor at Pharma Business Week Mylan Inc. confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an Abbreviated New Drug Application with the U.S. Food and Drug Administrat
4/21/14 - Lupin Appoints Theresa Stevens as Chief Corporate Development Officer
Prior to joining Lupin, Theresa was with Aptalis pharma as the Chief Corporate Development Officer responsible for Mergers& Acquisitions, Strategy and Global Business Development. Before Aptalis, Theresa was with Novartis for 9+ years and held positions of increasing responsibility including Head, Global BD&L for General Medicines, Executive Direct
4/21/14 - Par Pharmaceutical Begins Shipment of Potassium Chloride Extended-Release Capsules
By a News Reporter-Staff News Editor at Pharma Business Week Par Pharmaceutical Companies, Inc. announced that it has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for potassium chloride extended-release capsules, USP, in 600 mg and 750 mg strengths. According to IMS Health data, annua
4/21/14 - Teva Announces First Approval and Launch of Generic Lovaza Capsules in the United States
Teva believes it is first-to-file and thus far is the only Company to receive an approval from FDA. Teva plans to commence shipping immediately. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in approximately 60 countries.
4/21/14 - United States Crohn's Disease Report 2014 - Drug Forecast and Market Analysis to 2022
By a News Reporter-Staff News Editor at Gastroenterology Week Research and Markets has announced the addition of the "PharmaPoint: Crohn's Disease- US Drug Forecast and Market Analysis to 2022" report to their offering. The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inf
4/19/14 - Particle Sciences and Actavis Enter into Joint Development Agreement
By a News Reporter-Staff News Editor at Marketing Weekly News Particle Sciences, a drug delivery Contract Development and Manufacturing Organization, announced that they have entered into an exclusive agreement with Actavis plc, a leading specialty pharmaceutical company, to develop an unnamed complex generic product. Actavis will have responsibi
4/19/14 - Some generic drugs have had eye-popping price spikes [Fort Worth Star-Telegram :: ]
April 19 Pharmacist Larry Cowan can flip through his records and spot the generic drugs that have taken big price jumps in the past year or so. "Now the price is close to 10 times that," said Cowan, owner of Glenview Professional Pharmacy in Richland Hills. While the FDA in the past month removed doxycyline from its shortage list, it still costs
4/19/14 - Teva Announces Supreme Court Denial of Request for Interim Relief to Stay Court of Appeals Ruling for COPAXONE Patent Due to the Potential for the Company to Recover Patent Infringement Damages
Teva Pharmaceutical Industries Ltd. announced that while the Chief Justice of the United States found that Teva had demonstrated a fair prospect of success on the merits in its appeal of a decision from the United States Court of Appeals for the Federal Circuit that invalidated the claim of U.S. Teva will continue pursuing its appeal in the S
4/18/14 - Actavis Confirms Favorable Ruling in Generic Lialda Patent Suit
By a News Reporter-Staff News Editor at Health& Medicine Week Actavis plc confirmed that the United States Court of Appeals for the Federal Circuit has reversed a lower court ruling that Actavis' generic version of Shire's Lialda infringes United States Patent No. 6,773,720. Actavis' Abbreviated New Drug Application for its generic version of Lia
4/18/14 - Court declines to block drug ruling in patent case
WASHINGTON The Supreme Court has declined to temporarily block a lower court ruling that opens the world's best-selling multiple sclerosis drug to competition from generic rivals. Teva claims the U.S. Court of Appeals for the Federal Circuit wrongly overturned five of its patents for the drug. That ruling allows rivals Mylan Inc., Momenta Pharma
4/18/14 - Lannett Gets FDA Approval for Diazepam Oral Solution (Concentrate), 5 mg/mL [Health & Beauty Close - Up]
Lannett Company, Inc. said that it has received approval from the U.S. Food and Drug Administration of its Abbreviated New Drug Application for Diazepam Oral Solution, 5 mg/ mL, a Schedule C-IV controlled drug. "We believe our ANDA for Diazepam Oral Solution, 5 mg/mL was the first bioequivalent Diazepam Oral Solution product approved by the FDA,"
4/18/14 - Perrigo Announces Launch Of Authorized Generic Version Of Taclonex Ointment Calcipotriene 0.005% / Betamethasone Dipropionate 0.064%
By a News Reporter-Staff News Editor at Health& Medicine Week Perrigo Company plc announced that it has initiated market launch and made its first shipments of the authorized generic version of LEO Pharma A/S' Taclonex Ointment. >From its beginnings as a packager of generic home remedies in 1887, Perrigo Company plc, headquartered in Ireland,
4/18/14 - Teva Introduces Generic Lunesta Tablets in the United States [Professional Services Close - Up]
Teva Pharmaceutical Industries announced the launch of the generic equivalent to Lunesta, 1, 2 and 3 mg, in the United States. According to a release, Lunesta Tablets, marketed by Sunovion Pharmaceuticals, had annual sales of approximately $852 million in the United States, according to IMS data as of December 2013. Teva Pharmaceutical Industries i
4/18/14 - TEVA, PFIZER SETTLE PATENT LAWSUIT
Teva Pharmaceutical Industries Ltd has settled a patent lawsuit with Pfizer Inc. In Mar 2014, a US court invalidated a patent covering Celebrex, giving Pfizer's rivals a chance to sell cheaper versions. With the settlement of the patent lawsuit, Teva can now launch a generic version of Pfizer's Celebrex in Dec 2014. According to Pfizer, Celebrex ge
Articles(s): 1 - 25 of 58     Next >>     Go To Page:


© 2014 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Drug Therapy Management Series Part II: Psychiatric Disorders
This lesson is supported by:
RxSchool
An Overview of Complementary and Alternative Medicine
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comRxProHealth.comPharmacyPages.comNursingJobSource.comNurseZone.comRN.com
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415